Funding for this research was provided by:
Conquer Cancer Foundation
National Institutes of Health (T32 CA 9071-36, R01 CA169702, R01 CA197296)
National Center for Advancing Translational Sciences (OCTRI #UL1TR000128, OCTRI #UL1TR000128)
Japan Society for the Promotion of Science (17H07016)
Bristol-Myers Squibb (International Immuno-Oncology Network grant)
Skip Viragh Foundation
National Cancer Institute (P50 CA062924, P50 CA062924)
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
Sidney Kimmel Foundation for Cancer Research (P30 CA006973)
Received: 10 September 2018
Accepted: 26 October 2018
First Online: 13 November 2018
Ethics approval and consent to participate
: Institutional review board (IRB) approval was obtained before initiation of the clinical trial. As this was a retrospective study, IRB approved the request for waiver for patients’ consents. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC).
: Not applicable
: L.Z. receives grant supports from Bristol-Meyer Squibb, Merck, iTeos, Amgen, Gradalis, and Halozyme, and receives the royalty for licensing GVAX to Aduro Biotech. L.Z. is a paid consultant/Advisory Board Member at Biosynergies, Oncorus, Alphamab, Merck, NovaRock and AstroZeneca. E.M.J. receives the royalty for licensing GVAX to Aduro Biotech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.